Management of Immune Checkpoint Inhibitor Toxicities

Immune checkpoint inhibitors (ICIs) have radically changed the clinical outcome of several cancers with durable responses. CTLA-4 (cytotoxic T lymphocyte antigen-4), PD-1 (programmed cell death protein 1) or PDL-1 (programmed cell death ligand protein 1) represent ICIs that can be used as monotherap...

Descripción completa

Detalles Bibliográficos
Autores principales: Durrechou, Quentin, Domblides, Charlotte, Sionneau, Baptiste, Lefort, Felix, Quivy, Amandine, Ravaud, Alain, Gross-Goupil, Marine, Daste, Amaury
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7533913/
https://www.ncbi.nlm.nih.gov/pubmed/33061607
http://dx.doi.org/10.2147/CMAR.S218756

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7533913/
https://www.ncbi.nlm.nih.gov/pubmed/33061607
http://dx.doi.org/10.2147/CMAR.S218756

Ejemplares similares